SARS-CoV-2 spike protein–derived peptide epitopes (SARS-CoV-2 S-epitopes)

SARS-CoV-2 spike protein–derived peptide epitopes are specific amino acid sequences within the viral spike (S) glycoprotein that trigger an immune response. The spike protein is the primary surface component used by the virus to bind to the human ACE2 receptor and enter host cells. These epitopes are critical targets for both natural immunity and vaccine development, as they contain the Receptor Binding Domain (RBD) and the N-terminal domain (NTD) where most neutralizing antibodies bind (Source: Nature, PubMed: 32540901). In therapeutic contexts, these peptides are used in the design of peptide-based vaccines and as diagnostic tools to monitor T-cell and B-cell reactivity. By isolating highly conserved epitopes, researchers aim to develop 'pan-coronavirus' vaccines that remain effective against emerging variants. Drugs such as monoclonal antibodies specifically target these epitopes to block viral entry, while vaccines use the genetic code or protein fragments of these epitopes to train the immune system to recognize the virus (Source: Science, PubMed: 32431294).

Other names

Spike protein peptidesS-protein epitopesSARS-CoV-2 S-derived peptidesSevere acute respiratory syndrome coronavirus 2 spike glycoprotein epitopes

These peptide epitopes serve as the primary antigenic determinants that are recognized by the host immune system. When delivered via vaccines (mRNA, viral vector, or protein subunit), they are presented by Major Histocompatibility Complex (MHC) molecules to T-cells and recognized by B-cell receptors, leading to the production of neutralizing antibodies and the generation of cellular immunity to prevent or limit SARS-CoV-2 infection (Source: NIH, PubMed: 32783919).